"N Engl J Med"[journal] 检索结果

141. Alternative Complement Pathway, Iptacopan, and IgA Nephropathy.

作者: Felix Poppelaars.;Bernardo Faria.;Joshua M Thurman.
来源: N Engl J Med. 2025年392卷19期1975页

142. Longitudinal Changes in Airway Mucus Plugs and FEV1 in COPD.

作者: Sofia K Mettler.;Pietro Nardelli.;Monica Iturrioz Campo.;Rubén San José Estépar.;Padma P Manapragada.;Mostafa Abozeed.;Muhammad Usman Aziz.;Mohd Zahid.;Scott Grumley.;Hrudaya P Nath.;Andrew Yen.;Sushilkumar Sonavane.;Christian F Clarenbach.;Wei Wang.;Carrie L Pistenmaa.;George R Washko.;Raúl San José Estépar.;Michael H Cho.;Alejandro A Diaz.; .; .
来源: N Engl J Med. 2025年392卷19期1973-1975页

143. Xenotransplantation - Long Awaited, Much Learned, Much More to Be Learned.

作者: Sandy Feng.
来源: N Engl J Med. 2025年392卷19期1971-1972页

144. Targeting Orexin Receptors to Treat Narcolepsy.

作者: Clifford B Saper.
来源: N Engl J Med. 2025年392卷19期1968-1971页

145. Progress toward Mitigating Disability Progression in Multiple Sclerosis.

作者: Peter A Calabresi.
来源: N Engl J Med. 2025年392卷19期1966-1968页

146. Case 14-2025: A 29-Year-Old Woman with Peritonsillar Swelling and Bleeding.

作者: Rahmatullah Wais Rahmati.;Katherine L Reinshagen.;Rosh K V Sethi.;David S Shulman.;Emily M Hartsough.
来源: N Engl J Med. 2025年392卷19期1954-1964页

147. Plight on the Pickleball Court.

作者: Catherina X Pan.;Anand Vaidya.;Daniel P Marcusa.;Jacob A Burns.;Thomas Michel.
来源: N Engl J Med. 2025年392卷19期e46页

148. Torsion of a Mature Cystic Ovarian Teratoma.

作者: Xiaodong Zhang.;Peng Xie.
来源: N Engl J Med. 2025年392卷19期e45页

149. Hair Tourniquet.

作者: Anton Ivan Moorees.;Dirk Vervloessem.
来源: N Engl J Med. 2025年392卷19期e44页

150. Ph-Positive Acute Lymphoblastic Leukemia - 25 Years of Progress.

作者: Robin Foà.
来源: N Engl J Med. 2025年392卷19期1941-1952页

151. Second-Line Antiretroviral Therapy for Children Living with HIV in Africa.

作者: Victor Musiime.;Mutsa Bwakura-Dangarembizi.;Alexander J Szubert.;Vivian Mumbiro.;Hilda A Mujuru.;Cissy M Kityo.;Abbas Lugemwa.;Katja Doerholt.;Chishala Chabala.;Shafic Makumbi.;Veronica Mulenga.;Helen McIlleron.;David Burger.;Eva Natukunda.;Clare Shakeshaft.;Kyomuhendo Jovia Linda.;Kusum Nathoo.;Lara Monkiewicz.;Ibrahim Yawe.;Monica Kapasa.;Mary Nyathi.;Joyce Lungu.;Bwendo Nduna.;Wedu Ndebele.;Annabelle South.;Mwate Mwamabazi.;Godfrey Musoro.;Anna Griffiths.;Khozya Zyambo.;Rashidah Nazzinda.;Kevin Zimba.;Yingying Zhang.;Simon Walker.;Anna Turkova.;A Sarah Walker.;Alasdair Bamford.;Diana M Gibb.; .
来源: N Engl J Med. 2025年392卷19期1917-1932页

Children living with human immunodeficiency virus (HIV) have limited options for second-line antiretroviral therapy (ART).

152. Oveporexton, an Oral Orexin Receptor 2-Selective Agonist, in Narcolepsy Type 1.

作者: Yves Dauvilliers.;Giuseppe Plazzi.;Emmanuel Mignot.;Gert Jan Lammers.;Rafael Del Río Villegas.;Ramin Khatami.;Mitsutaka Taniguchi.;Anson Abraham.;Yaming Hang.;Harisha Kadali.;Marta Lamberton.;Sarah Sheikh.;Ellie Stukalin.;Rachel Neuwirth.;Todd J Swick.;Shinichiro Tanaka.;Christian von Hehn.;Philipp von Rosenstiel.;Hao Wang.;Alice Cai.;Melissa Naylor.;Tina Olsson.
来源: N Engl J Med. 2025年392卷19期1905-1916页

Narcolepsy type 1 is a disorder of hypersomnolence caused by a loss of orexin neurons, which results in low orexin levels in the brain.

153. Loss of Subsidized Drug Coverage and Mortality among Medicare Beneficiaries.

作者: Eric T Roberts.;Jessica Phelan.;Aaron L Schwartz.;Ellen Meara.;Dominic Ruggiero.;Lilly Estenson.;Rachel M Werner.;José F Figueroa.
来源: N Engl J Med. 2025年392卷20期2025-2034页

A total of 14 million Medicare beneficiaries receive the Low-Income Subsidy (LIS), which reduces cost sharing in Medicare Part D. Losing the LIS may impede medication access and affect mortality.

154. Paget's Disease of Bone.

作者: Masashi Hasebe.;Akihiro Hamasaki.
来源: N Engl J Med. 2025年392卷19期1953页

155. AI-Driven Clinical Documentation - Driving Out the Chitchat?

作者: Gordon D Schiff.
来源: N Engl J Med. 2025年392卷19期1877-1879页

156. Driving Jackson.

作者: Rajeev Raghavan.
来源: N Engl J Med. 2025年392卷19期1879-1881页

157. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.

作者: Louis J Aronne.;Deborah Bade Horn.;Carel W le Roux.;Wayne Ho.;Beverly L Falcon.;Elisa Gomez Valderas.;Sagar Das.;Clare J Lee.;Leonard C Glass.;Cagri Senyucel.;Julia P Dunn.; .
来源: N Engl J Med. 2025年

Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 diabetes is unknown.

158. Sixty Years of Community Health Centers - An Anniversary at a Crossroads.

作者: Alexander E Jacobs.
来源: N Engl J Med. 2025年392卷19期1875-1877页

159. Efruxifermin in Compensated Liver Cirrhosis Caused by MASH.

作者: Mazen Noureddin.;Mary E Rinella.;Naga P Chalasani.;Guy W Neff.;K Jean Lucas.;Manuel E Rodriguez.;Madhavi Rudraraju.;Rashmee Patil.;Cynthia Behling.;Mark Burch.;Doreen C Chan.;Erik J Tillman.;Arian Zari.;Brittany de Temple.;Reshma Shringarpure.;Meena Jain.;Timothy Rolph.;Andrew Cheng.;Kitty Yale.
来源: N Engl J Med. 2025年

In phase 2 trials involving patients with stage 2 or 3 fibrosis caused by metabolic dysfunction-associated steatohepatitis (MASH), efruxifermin, a bivalent fibroblast growth factor 21 (FGF21) analogue, reduced fibrosis and resolved MASH. Data are needed on the efficacy and safety of efruxifermin in patients with compensated cirrhosis (stage 4 fibrosis) caused by MASH.

160. Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.

作者: Stephen J Nicholls.;Adam J Nelson.;Marc Ditmarsch.;John J P Kastelein.;Christie M Ballantyne.;Kausik K Ray.;Ann Marie Navar.;Steven E Nissen.;Mariko Harada-Shiba.;Danielle L Curcio.;Annie Neild.;Douglas Kling.;Andrew Hsieh.;Julie Butters.;Brian A Ference.;Ulrich Laufs.;Maciej Banach.;Roxana Mehran.;Alberico L Catapano.;Yong Huo.;Michael Szarek.;Violeta Balinskaite.;Michael H Davidson.; .
来源: N Engl J Med. 2025年

Obicetrapib is a highly selective cholesteryl ester transfer protein inhibitor that reduces low-density lipoprotein (LDL) cholesterol levels. The efficacy and safety of obicetrapib have not been fully characterized among patients at high risk for cardiovascular events.

结果排序

文献格式

出版时间

出版类型

出版语言